Orbimed Advisors Llc bought $16.1M of ADARx Pharmaceuticals (ADRX)
Executed Sep 28, disclosed Sep 30, 2 days later.
Not yet measured: the 21-session window has not closed, or the prices around it are not on record.
Orbimed Advisors Llc (Director) filed 17 Form 4 reports as a reporting entity in the trailing twelve months (9 purchases, 8 sales, 1 filed past the two-business-day deadline), most often in Sionna Therapeutics, Inc. (SION). Across 7 priced purchase filings, the average 21-session return was +16.9% from execution and +18.9% from disclosure (delay-adjusted; derived). The largest single filing was $38.9M of ELVN (858,646 sh across 3 lots, as filed), executed Jun 22.
Healthcare · ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a bro…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→